Aadi Bio (WHWK): Stock Price

Aadi Bioscience Inc (WHWK) specializes in precision therapy for rare oncological pathologies, ensuring steady demand through long-term treatment cycles, with the indicator standing at 3.25. This price chart reflects the asset's market volatility. The business is implementing AI nanoparticle simulations to automate laboratories, while management under David Lennon is optimizing the test portfolio to bolster shareholder confidence.

aadibio.com - WHWK Stock Quotes (period 03/20/2025 - 11/12/2026)

Metric breakdowns and analytics for Aadi Bio (WHWK)

- current price and projected stock value:

Stock Quotes Aadi Bioscience Inc|WHWK - Consensus Target

- stock exchange capitalization data:

Market Capitalization Aadi Bioscience, Inc.|WHWK - Value Adjusted for Debt and Cash

- book capitalization information:

Accounting Value per Share Aadi Bioscience|WHWK - Company Net Assets|Market Value to Book Value Ratio aadibio.com|WHWK - Company Total Assets

- debt burden and liquidity indicators:

- financial results and valuation multiples details:

WHWK - Company Net Income|Expected Profit Aadi Bioscience Inc|WHWK - Company Value to Net Income|Projected Price to Earnings Aadi Bioscience Inc|WHWK - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Aadi Bioscience, Inc.|WHWK - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Aadi Bioscience|WHWK - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months aadibio.com|WHWK - Earnings per share increase in current year|Earnings growth forecast for next year Aadi Bioscience Inc

Comprehensive company analysis:WHWK Aadi Bioscience

Price reflects the market consensus on the value of a business stake, forming as the result of the interaction between supply and demand based on all of the issuer's fundamental drivers. For Aadi Bioscience Inc (WHWK), the price action on the exchange chart confirms the capitalization of innovations in precision oncology and the efficacy of Fyarro in treating rare mTOR mutations.

Who Aadi Bioscience Inc competes with